Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833149 | 0.96 | ALDH1A1 (0.51) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL27996225 | 0.85 | ALDH1A1 (0.39) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL4830748 | 0.82 | KMT2A (0.50) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL4870900 | 0.82 | KDM4E (0.48) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL4866800 | 0.82 | ADORA1 (0.46) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL4835218 | 0.78 | ADORA1 (0.51) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL3117627 | 0.76 | IKBKB (0.47) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL2903130 | 0.75 | KDM4E (0.55) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL16345765 | 0.74 | ALDH1A1 (0.49) | ALDH1A1HSD17B10ALOX15KDM4EHPGD | |
| SCHEMBL5243215 | 0.72 | PRKCZ (0.59) | ALDH1A1HSD17B10KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473434-B | Substituted quinolone derivative or pharmaceutically acceptable salt or stereoisomer thereof, and medicinal composition and application thereof | 上海海和药物研究开发股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3339294-B1 | QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | JINAN UNIVERSITY (CN) | 2018-09-20 | — | — | US | disclosed |
| CN-108473434-A | Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application | 暨南大学 | 2018-08-31 | — | — | CN | disclosed |
| EP-3339294-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | Jinan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017028797-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | 暨南大学 | 2017-02-23 | — | — | WO | disclosed |
| CN-102464667-B | Five-membered heterocycle pyrimidine compounds, preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2014-06-04 | — | — | CN | disclosed |
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| CN-1964978-A | Furanopyrimidine compounds effective as potassium channel inhibitors | XENTION LTD (GB) | 2007-05-16 | — | — | CN | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1758909-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005121149-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION DISCOVERY LTD. (GB) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NRAS, AXL, ABL1 | ALDH1A1 3691/4885HSD17B10 3233/4885ALOX15 2440/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | ALDH1A1 159/4885HSD17B10 3342/4885ALOX15 201/4885 |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | NRAS, AXL, ABL1 | ALDH1A1 3691/4885HSD17B10 3233/4885ALOX15 2440/4885 |
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | KCNH3, HCN4, KCNH2 | ALDH1A1 3825/4885HSD17B10 2473/4885ALOX15 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.